Telomeric refinement of the MCKD1 locuson chromosome 1q21**See Editorial by Bichet and Fujiwara, p. 864.  by Wolf, Matthias T.F. et al.
Kidney International, Vol. 66 (2004), pp. 580–585
Telomeric refinement of the MCKD1 locus
on chromosome 1q211
MATTHIAS T.F. WOLF, BRUNO VAN VLEM, HANS C. HENNIES, ISABELLA ZALEWSKI,
STEPHANIE M. KARLE, MARKUS PUETZ, FRANZISKA PANTHER, EDGAR OTTO,
ARNO FUCHSHUBER, NORBERT LAMEIRE, BART LOEYS, and FRIEDHELM HILDEBRANDT
Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, Michigan; Department of Internal
Medicine, Renal Division, Ghent University Hospital, Ghent, Belgium; Max-Delbrueck Center for Molecular Medicine,
Berlin-Buch, Germany; University Children’s Hospital, Freiburg University, Freiburg, Germany; Centrum Medische Genetica,
Ghent University Hospital, Ghent, Belgium; and Department of Human Genetics, University of Michigan, Ann Arbor, Michigan
Telomeric refinement of the MCKD1 locus on chromosome
1q21.
Background. Autosomal-dominant medullary cystic kidney
disease type 1 (MCKD1) is a tubulointerstitial nephropathy that
causes renal salt wasting and end-stage renal failure in the sixth
decade of life. The chromosomal locus for MCKD1 was local-
ized to chromosome 1q21 in a Cyprotic kindred. In this report
we describe further refinement of the critical genetic region by
a recombination in a Belgian kindred.
Methods. Clinical data and blood samples of 33 individuals
from a large Belgian kindred were collected and high-resolution
haplotype analysis was performed.
Results. In the Belgian kindred linkage to the MCKD1 locus
on chromosme 1q21 was found with a logarithm of odds (LOD)
score significant for linkage. A recombination in individual III:7
for marker D1S2624 refines the critical genetic region to 2.1 Mb.
In this kindred a wide variety of clincial symptoms and age of
onset of renal failure was detected.
Conclusion. We confirm the MCKD1 locus on chromosome
1q21 and show further refinement of the MCKD1 locus to 2.1
Mb. This allowed us to exclude another 17 genes as positional
candidate genes.
Autosomal-dominant medullary cystic kidney disease
(MCKD) is a progressive tubulointerstitial nephropathy.
Clinical characteristics for MCKD are salt wasting, de-
creased urinary concentration ability, and end-stage renal
disease (ESRD) [1]. In some kindreds an association
with hyperuricemia was found. In MCKD small cor-
ticomedullary cysts are common, but not always de-
tected. Kidney size is normal or slightly reduced [2]. Two
gene loci for MCKD have been described. For MCKD1
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(OMIM 17400) a locus was published on chromosome
1q21 in a large Cypriotic kindred [3]. In an Italian kindred
the MCKD2 locus was localized to chromosome 16p12
[4]. Clinical symptoms are very similar in MCKD1 and
2. However, in MCKD2 gout is more frequent and there
is more severe hyperuricemia. Age of onset of renal fail-
ure is 32 years of age in MCKD2 compared to 62 years
in MCKD1 [4]. Otherwise, these two disease variants are
clinically undistinguishable.
MCKD shows a renal histologic triad of (1) tubu-
lar basement disintegration, (2) tubular atrophy with
cyst development at the corticomedullary border, and
(3) interstitial cell infiltration associated with fibrosis
[5]. Neither imaging results, nor pathologic findings are
pathognomonic for MCKD. The condition shares clin-
ical and morphologic similarities with recessive juvenile
nephronophthisis (NPH) [6]. However, in NPH end-stage
renal failure occurs in the first two decades of life. More-
over, NPH is inherited in an autosomal-recessive pattern,
whereas MCKD is autosomal-dominant.
The MCKD1 locus on chromosome 1q21 has been con-
firmed by several groups [7–10]. However, the critical ge-
netic region could never be narrowed down sufficiently
to warrant mutational analysis of positional candidate
genes. For MCKD2 the responsible gene has recently
been identified. Missense mutations in exons 4 and 5 of
the uromodulin (UMOD) gene have been described in at
least 20 different kindreds [11–14]. These mutations al-
ter the encoded Tamm-Horsfall protein (THP), the most
abundant protein in human urine [13]. No related candi-
date gene can be found in the critical chromosomal region
for MCKD1 on chromosome 1q21.
METHODS
Patient recruitment
Blood samples were available from 33 individuals of
a large Belgian kindred, in which MCKD segregated
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Fig. 1. Pedigree of the Belgian MCKD1 kindred. Circles denote fe-
males, squares denote males. Filled symbols denote 11 individuals af-
fected by MCKD1, crosshatches denote deceased individuals, and ques-
tion marks indicate that these indivduals are too young to exclude the
diagnosis of MCKD. Roman numerals denote generations.
(Fig. 1). Clinical data were obtained from an additional
four affected individuals who were deceased. The age
at diagnosis, the age at onset of ESRD, hyperuricemia,
imaging data, and biopsy results were reviewed, if avail-
able. Clinical criteria used for the diagnosis of MCKD
were (1) chronic renal failure, (2) defective urine con-
centration ability (<800 mOsm/L after overnight water
deprivation), polyuria (>3 L/day), (3) compatibility of
the pedigree with autosomal-dominant inheritance, and
(4) at least one pedigree member with chronic renal fail-
ure in whom renal biopsy showed tubular-interstitial fi-
brosis with infiltrates, tubular atrophy, and thickening of
the tubular basement membrane. Hyperuricemia was de-
fined as serum uric acid concentration >1 SD greater than
the normal values for age and gender (both genders 5 to
10 years 4.1 ± 1 mg/dL; female 12 years 4.5 ± 0.9 mg/dL;
15 years 4.5 ± 0.9 mg/dL; and ≥18 years 4.0 ± 0.7 mg/dL;
male 12 years 4.4 ± 1.1 mg/dL; 15 years 5.5 ± 1.1 mg/dL;
and ≥18 years 6.2 ± 0.8) [15].
The study was approved by the ethics committees of the
Albert-Ludwigs-University Freiburg and the University
of Michigan. All participating family members provided
informed consent.
Haplotype analysis
Genomic DNA was isolated by standard methods di-
rectly from blood samples using the QIAamp blood kit
(Qiagen, Valencia, CA, USA). Haplotype analysis was
performed in 33 individuals (including six affected indi-
viduals) (Fig. 1). Haplotypes were inferred from segrega-
tion in 13 additional individuals (four additional affected
individuals). For haplotype analysis we used ten con-
secutive polymorphic microsatellite markers that span
the critical MCKD1 region in the following order: cen –
D1S305 – D1S29H23g∗ – D1S29H23e∗ – D1S29H23c∗ –
D1S303 – D1S1595 – D1S243J18c∗ – D1S336K24h∗ –
D1S336K24a∗ – D1S2624 – tel. To characterize the recom-
bination in individual III:7, eight additional markers were
genotyped (D1S1153 – D1S336mw19∗ – D1S336mw22∗
– D1S336mw25∗ – D1S2624mw4∗ – D1S2715 – D1S394
– D1S1653) (Fig. 2). Marked with an asterisks are ten
novel polymorphic makers, created by searching for mi-
crosatellite markers using a list of di-, tri-, and tetranu-
cleotide repeats in a BLAST search (data available from
the authors) [16]. To analyze linkage to the MCKD2
locus, we performed haplotype analysis with 12 polymor-
phic microsatellite markers: cen – D16S3060 – D16S764 –
D16S499 – D16S3056 – D16S3036 – D16S3041 – D16S412
– D16S417 – D16S420 – D16S3113 – D16S401 – D16S3116
– tel. Fluorescently labeled polymerase chain reaction
(PCR) products were detected by a Genetic Analyzer
3100TM (Applied Biosystems, Foster City, CA, USA) and
were analyzed by the GenotyperTM software. Two-point
logarithm of odds (LOD) score calculations were per-
formed by the Linkage program software package [17],
using an autosomal-dominant model with full penetrance,
and a gene frequency for MCKD1 of 0.0001. For calcu-
lations an “affecteds-only” strategy was chosen, because
of the age related penetrance in MCKD1.
RESULTS
Clinical data
In this Belgian kindred 33 individuals were available
for genetic analysis. In six individuals the diagnosis of
MCKD was made. The clinical and laboratory findings of
the patients are shown in Table 1. The age at presenta-
tion ranged from 29 to 53 years (median 41 years). Age
at ESRD varied between 34 and 49 years (median 41
years). The progression from first symptoms at presen-
tation (polyuria, polydipsia, or anemia) to ESRD varied
between 6 months and 11 years (data not shown). Three
individuals (III:1, III:8, and III:9) received kidney trans-
plants at the age of 41, 43, and 50 years, respectively.
Hypertension was found in one individual (III:24). Hype-
ruricemia was present in two individuals (III:2 and III:8).
Gout was not reported in any patient. Ultrasound in four
patients revealed small kidneys in two affected individu-
als (III:1 and III:2), and small medullary cysts in two other
patients. Histology was available in indivdual III:2, ex-
hibiting microcysts, atrophic tubuli, thickened basement
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Fig. 2. Results of the haplotype analysis of 18
markers at the MCKD1 locus in 16 individu-
als from the Belgian MCKD1 kindred. Circles
denote females, squares denote males. Filled
symbols denote affected individuals. Arrows
denote individuals in whom DNA was avail-
able for haplotype analysis. Inferred haplo-
types are shown in parenthesis. Differently
shaded bars symbolize haplotypes. Paternal
haplotypes are drawn to the left, maternal
haplotypes to the right. Marker positions are
indicated with left individuals. Assignment of
the disease associated haplotype to I:2 is arbi-
trary. The black haplotype showed complete
cosegregation with the phenotype in all six liv-
ing affected individuals of this kindred (data
not shown). The question marks in individu-
als IV:6 – IV:8 indicate that these persons are
too young to exclude the diagnosis of MCKD.
Note the recombination event in individual
III:7, which identifies marker D1S2624 as a
new telomeric flanking marker. The thin line
in the left haplotype of individual III:7 shows
the uninformative region, which makes it im-
possible to distinguish between the black and
the white haplotype.
Table 1. Synopsis of clinical data, imaging results, and renal histology in the Belgian MCKD1 kindred investigated
Age at Age at Age at Creatinine Histology
presentation ESRD/death NTX Clinical clearance (kidney
Individual Gender years years years symptoms mL/min/1.73 m2 Imaging biopsy)
II:2 M ND 34 — CRI ND ND ND
II:4 M ND 38 — CRI ND ND ND
II:6 F ND ND — CRI ND ND ND
II:13 F ND ND — CRI ND ND ND
III:1 M 29 41/51 41 CRI ND US: small kidneys
bilaterally
ND
III:2 M 38 41 — CRI,
Hyperuricemia
17.5 US/CT: small
kidneys bilaterally
Global glomerulosclerosis,
microcysts, atrophic
tubuli, thickened
basement membrane
III:7 F 53 — — CRI 65 US: small cysts in
both kidneys, mi-
crocalcifications
ND
III:8 F 49 49 50 CRI,
Hyperuricemia
ND ND ND
III:9 M 41 43 43 CRI ND ND ND
III:23 F 40 — — CRI 23.5 US: multiple small
medullary and
cortical cysts
bilaterally
ND
III:24 M 42 — — Mild renal
insufficiency,
hypertension,
hyperuricemia
51 ND ND
Abbreviations are: CRI, chronic renal insufficiency; ESRD, end-stage renal disease, ND, no data; NTX, renal transplantation; US, ultrasound.
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Table 2. Two-point logarithm of odds (LOD) scores at the MCKD1 locus for the Belgian MCKD kindred
Two-point LOD score at 
Marker 0.000 0.001 0.010 0.050 0.100 0.200 0.300 0.400
D1S305 1.146 1.143 1.115 0.991 0.836 0.532 0.260 0.068
D1S29H23g 2.034 2.030 1.989 1.805 1.569 1.076 0.578 0.163
D1S29H23e 1.458 1.456 1.438 1.345 1.204 0.861 0.470 0.128
D1S29H23c 1.832 1.828 1.790 1.619 1.399 0.939 0.481 0.122
D1S303 0.469 0.467 0.451 0.380 0.299 0.162 0.066 0.014
D1S1595 1.614 1.611 1.579 1.433 1.244 0.850 0.455 0.129
D1S243J18c 1.331 1.327 1.295 1.151 0.970 0.613 0.294 0.073
D1S336K24h 1.166 1.162 1.133 1.004 0.843 0.533 0.259 0.067
D1S336K24a 0.640 0.683 0.619 0.535 0.435 0.255 0.114 0.028
D1S2624 −1.602 −0.921 −0.046 0.483 0.576 0.452 0.225 0.050
membrane, and global glomerulosclerosis, thus confirm-
ing the diagnosis of MCKD.
Linkage analysis
We were able to exclude linkage in this kindred to the
MCKD2 locus on chromosome 16p12 (data not shown).
Linkage analysis with ten polymorphic markers from
the critical MCKD1 region revealed cosegregation of
a haplotype of marker alleles with the affected status
for MCKD. Two-point LOD scores were positive at the
MCKD1 locus. The maximum two-point LOD score was
2.034 ( = 0) for D1S29H23g, thus confirming significant
linkage in this kindred to the MCKD1 locus (Table 2). In
linkage studies on candidate regions where only a few
polymorphic markers are tested, the criterion of signifi-
cance for linkage can be relaxed to >2.0 (from >3.0 as
necessary in a total genome search with multiple tests
of approximately 400 markers) [17]. A recombination
event in III:7 defined marker D1S2624 as distally flanking
(Fig. 2). By filling in additional eight markers the recom-
bination was confirmed. Since marker D1S305 was de-
scribed as the centromeric flanking marker to MCKD1 in
a Welsh kindred [9], our data restrict the critical MCKD1
region by 1.2 Mb to a minimum interval of 2.1 Mb.
DISCUSSION
In this large Belgian kindred we demonstrate linkage
to the MCKD1 locus on chromosome 1q21 and further
refine the critical genetic region. Concerning the clinical
data this kindred reveals an interesting difference to the
previously published cases [3, 7–10]. MCKD1 has been
described as leading to ESRD in the sixth decade [3, 9,
10]. Here we found a median age of 41 years at onset
of ESRD, which is clearly younger than published previ-
ously. Stavrou et al [10] found that succeeding generations
were affected earlier than their anchestors. They hypoth-
esized the mechanism of genetic anticipation to be active.
The earlier age of onset in our kindred would be com-
patible with these findings. Furthermore, we found the
presence of hypertension in only one individual, which
is different to a percentage of 51.4% of the affecteds de-
scribed by Stavrou et al. Also Cohn et al [7] described
hypertension as a common characteristic of MCKD1.
We detected hyperuricemia in two individuals. Hyper-
uricemia was not described in the kindreds of Auranen
et al [8] and Cohn et al [7]. However, Christodoulou et al
[3] stated, that the two families, in which MCKD1 was ini-
tially described, had a history of gout and hyperuricemia.
Stavrou et al [10] detected an elevated uric acid level in
50% of the gene carriers before onset of the disease. The
generally described mild symtoms, the intrafamiliar vari-
ability concerning the age of onset and the progression to
ESRD are also found in this Belgian kindred. Although
cysts are not an essential criterion for the diagnosis of
MCKD [2], they may be helpful in making the diagno-
sis. Therefore, it is remarkable to realize how early in the
course of the disease cysts can appear, for example in
III:7, who developed cysts in both kidneys.
Initially, the MCKD1 region was described to be 7.1 Mb
long between marker D1S498 and D1S2125 [3]. We pre-
viously refined the critical genetic region to 3.3 Mb with
the new centromeric flanking marker D1S305 [9]. The
new telomeric recombination event we detected here in
III:7 narrows down the critical genetic region to 2.1 Mb
with the flanking marker D1S2624. An additional refine-
ment of up to 300 kb would have been possible, if markers
D1S336mw25 and D1S2624mw4 were not uninformative.
This refinement allowed us to exclude 17 positional can-
didate genes from the critical genetic region.
Recently, we published an approach toward refinement
of the MCKD1 region based on the hypothesis of hap-
lotype sharing [18]. Although this approach provides a
useful opportunity to narrow down the criticial region,
there is still a certain degree of insecurity, that sharing
of this haplotype may have occurred by chance. This
risk is eliminated by data based on true recombinations,
such as we present here. The Belgian kindred studied
here did not share the haplotype we described previously
[18].
Within the new defined critical genetic region a vari-
ety of interesting candidates are found on the basis of
similarities to the pathomechanisms of other renal cystic
diseases. Mucin 1 (MUC1), also called peanut-reactive
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urinary mucin, is a cell surface glycoprotein that is
involved in actin binding and in the structure of the cy-
toskeleton. MUC1 is interacting with E-cadherin and b-
catenin, proteins that also colocalize and coprecipitate
with polycystin-1 (PKD1) [19] and inversin (INVS) [20],
which causes a similar renal histology in NPH type 2.
Moreover, MUC1 includes a variable number tandem re-
peat (VNTR), which might increase the propensity for
spontaneous deletions. Thrombospondin 3 (THBS3) is
involved in cell adhesion and has an epidermal growth
factor (EGF)-like domain, as does UMOD, the pro-
tein altered in MCKD2. Additionally, Vos et al [21]
demonstrated THBS3 expression in mouse kidney, and
interaction between THBS1 and transforming growth
factor-b (TGF-b) was published [22]. TGF-b is known
to be involved in renal fibrosis [22], which is part of
the MCKD histology. The secretory carrier membrane
protein 3 (SCAMP3) is part of the post-Golgi trans-
port system. In autosomal-dominant polycystic kidney
disease (ADPKD) altered Golgi function and impaired
basolateral exocytosis in renal epithelia was shown [23].
Furthermore, SCAMP3 and epidermal growth factor re-
ceptor (EGFR) colocalize and coimmunoprecipitate [24].
EGFR overexpression was described in cpk mice, an ani-
mal model for autosomal-recessive polycystic kidney dis-
ease (ARPKD) [25].
ASH1L encodes a putative transcripton factor that lo-
calizes to cell-cell tight junctions and to nuclei [26]. Lo-
calization to the tight junction raises a suspicion about
a role in cystogenesis [27]. Interestingly, also INVS is lo-
calized in nuclei and is involved in the cell cycle [28].
ARGHEF2 is a rho/rac guanine nucleotide exchange fac-
tor. Rho-related small guanosine triphosphatase (GT-
Pases) are involved in the regulation of signal transduc-
tion cascades from extracellular stimuli to the cell nucleus
and the cytoskeleton. Colocalization of the nucleotide
exchange factor GEF-H1 with tubulin was shown [29].
Different kinds of tubulins form microtubuli, which are
the “backbone” of cilia. Proteins that are altered in renal
ocular diseases such as PKD1, PKD2 [30], NPHP1, and
NPHP2 [31] have been detected in cilia. Moreover, coim-
munoprecipitation of NPHP1 and INVS with b-tubulin
was shown [32]. Misato belongs to the tubulin/FtsZ fam-
ily, which includes als a-, b-, and c-tubulin. FtsZ is the
prokaryotic ancestor of eukaryotic tubulin. Therefore,
misato seems to be another component of microtubuli
and may be involved in the structure of cilia. Moreover,
FtsZ proteins are responsible for cell division and thereby
misato has functional similarities to INVS [32]. The chap-
eronin containing TCP1 subunit 3 (CCT3), was cloned
from a human kidney cDNA library [33]. Interaction be-
tween eukaryotic chaperonin CCT and tubulin was de-
scribed by Llorca et al [34]. CCT3 also promotes activa-
tion of the anaphase-promoting complex, a complex in
which also INVS interacts [35].
We hope to alleviate the gene identification in MCKD1
by the refinement of the critical region described here,
and to thereby restrict the possible candiate genes.
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